Navigation Links
Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering
Date:11/18/2009

l/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes.

The transaction is expected to close on or about November 25, 2009, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.

The securities are being offered in each of the Canadian provinces of British Columbia, Alberta, Manitoba and Ontario by way of a prospectus supplement to Oncolytics' base shelf short form prospectus and in the United States pursuant to a prospectus supplement to Oncolytics' effective Form F-10 shelf registration statement (File # 333-151513) previously filed with the United States Securities and Exchange Commission on June 6, 2008, as amended on June 17, 2008, pursuant to the United States Securities Act of 1933, as amended. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at http://www.sec.gov, from the System for Electronic Document Analysis and Retrieval (SEDAR) website at http://www.sedar.com or from the underwriters at:

    Oppenheimer & Co. Inc.
    Attention: Syndicate Prospectus Department
    300 Madison Avenue, 5th Floor
    New York, NY, 10017
    Telephone number: (212) 667-8563
    Email: EquityProspectus@opco.com

    Canaccord Adams Inc.
    Attention: Ron Sedran
    Brookfield Place
    161 Bay Street, Suite 3000
    Toronto, Ontario, Canada
    M5J 2S1
    Telephone number (416) 869-3198
    Email: ron.
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Oncolytics Biotech Inc. announces approval for UK clinical trial
2. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
3. Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
4. AMA Optics Announces New Brightness Acuity Meter -- Documents Disabling Glare from Cataract
5. Tyco International Announces Exchange Rate for Quarterly Dividend
6. Shopko Announces Launch of e-Commerce Platform
7. Driven by Customer Feedback, BodyMedia, Inc. Announces Major Enhancements and Brand Change for GoWear Fit
8. Encorium Reports Third Quarter 2009 Financial Results; Announces Date of Annual Stockholder Meeting
9. United American Healthcare Corporation Announces Fiscal 2010 First Quarter Results
10. MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition
11. US Farms, Inc. Announces Completion of Construction for New 3000 Square Foot Greenhouse Shipping and Packing Facility for Nursery Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity of ... despite good use of oral anticoagulants, according to the ... Pilot Registry. The findings were presented for the first ... Professor Gregory Lip (Birmingham, UK). , Professor Lip said: ... on management practices of European cardiologists conducted since the ...
(Date:8/30/2014)... Spain Sunday 31 August 2014: A new ... and powered by heart motion was presented at ... Switzerland. The prototype device does not require battery ... the Cardiovascular Engineering Group at ARTORG, University of ... in today,s medical implants. Once they reach a ...
(Date:8/30/2014)... In a world where a typical response to conflict is ... a game app to teach another way. Launched in ... is a colorful way to encourage moral values playfully. ... double-duty by teaching players new ways to find happiness and ... for consistently taking the high road, the Ultimate Karma game ...
(Date:8/30/2014)... Atlanta based automotive group Jim Ellis Automotive joined ... awareness for ALS by participating in the popular ALS ... Vice President Jimmy Ellis all participated in the challenge ... on their Youtube page; https://www.youtube.com/watch?v=pxufyxVo9j0 . , In ... staff also took the opportunity to challenge various businesses ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... AND EFFECTIVE FOR COPD , Previous research has ... risk for adverse events or respiratory-related death in patients ... (COPD); however, a recent article shows this may not ... Spain, Argentina, and Uruguay reviewed the results of 27 ...
... research suggests that high-risk women with breast cancer who do ... for developing a second breast cancer than previously thought. ... sentinel node biopsy be considered at the time of prophylactic ... findings? , The increased risk of developing breast cancer ...
... could help bridge this knowledge gap, experts say , , ... of babies have a surprisingly low knowledge of child ... know or how they should act, a new study ... parents don,t know that 1-year-olds can,t tell the difference ...
... hospitalizing young children for influenza creates a significant economic ... preventive flu shots for children and the people with ... by Cincinnati Childrens Hospital Medical Center and presented May ... Honolulu, Hawaii. , After analyzing data in three U.S. ...
... surprisingly low-level knowledge of typical infant development and ... emotional growth, according research from the University of ... false parenting assumptions can not only impair parent-child ... stimulation, will be presented Sunday, May 4, at ...
... designed to block the neurotransmitter acetylcholine including common ... are more likely to be dependent in one or ... according to new findings from researchers at Wake Forest ... which involve a class of drugs known as anticholinergic ...
Cached Medicine News:Health News:News briefs: May issue of the journal Chest 2Health News:Second breast cancer may be greater than thought for high-risk women without BRCA mutations 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Young children hospitalized for flu associated with higher costs and higher risk illness 2Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Commonly used medications associated with impaired physical function in older adults 2
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... The annual meeting of the Chinese food industry is ... June, heavily focusing on the growing health market in China, and ... and discuss business developments in the country and beyond. ... and China continues to enjoy a global reputation for being a ...
... Amgen (Nasdaq: AMGN ) today announced the ... compared XGEVA ™ (denosumab) to Zometa ® (zoledronic ... 1,901 men with prostate cancer and bone metastases. The study, ... secondary endpoints and demonstrated XGEVA,s superiority compared to Zometa in ...
Cached Medicine Technology:Health on the Agenda at Food ingredients Asia-China Trade Show 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: